ethyl 6,6-dimethyl-3-oxo-heptanoate | 144363-49-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: ethyl 6,6-dimethyl-3-oxo-heptanoate
• 英文别名: ethyl 6,6-dimethyl-3-oxoheptanoate
• CAS: 144363-49-5
• 化学式: C₁₁H₂₀O₃
• 分子量: 200.278
• InChiKey: VRBKBGHSCKMGMS-UHFFFAOYSA-N

物化性质

• 沸点：
  227.8±8.0 °C(Predicted)
• 密度：
  0.950±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 6,6-dimethyl-3-oxo-heptanoate 、 原甲酸三乙酯 在 乙酸酐 作用下， 生成 C₁₄H₂₄O₄
  参考文献：
  名称：

  Affinity of 3-acyl substituted 4-quinolones at the benzodiazepine site of GABAA receptors

  摘要：

  The finding that alkyl 1,4-dihydro-4-oxoquinoline-3-carboxylate and N-alkyl-1,4-dihydro-4-oxoquinoline3-carboxamide derivatives may be high-affinity ligands at the benzodiazepine binding site of the GABA(A) receptor, prompted a study of 3-acyl-1,4-dihydro-4-oxoquinoline (3-acyl-4-quinolones). In general, the affinity of the 3-acyl derivatives was found to be comparable with the 3-carboxylate and the 3-carboxamide derivatives, and certain substituents ( e. g., benzyl) in position 6 were again shown to be important. As it is believed that the benzodiazepine binding site is situated between an alpha-and a gamma-subunit in the GABA(A) receptor, selected compounds were tested on the alpha(1)beta(2)gamma(2s), alpha(2)beta(2)gamma(2s) and alpha(3)beta(2)gamma(2s) GABAA receptor subtypes. The 3-acyl-4-quinolones display various degrees of selectivity for alpha(1)-versus alpha(2)- and alpha(3)- containing receptors, and high-affinity ligands essentially selective for alpha(1) over alpha(3) were developed. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.05.049
• 作为产物：
  描述：

  新庚酰氯 、 丙二酸单乙酯 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.17h， 以45%的产率得到ethyl 6,6-dimethyl-3-oxo-heptanoate
  参考文献：
  名称：

  Affinity of 3-acyl substituted 4-quinolones at the benzodiazepine site of GABAA receptors

  摘要：

  The finding that alkyl 1,4-dihydro-4-oxoquinoline-3-carboxylate and N-alkyl-1,4-dihydro-4-oxoquinoline3-carboxamide derivatives may be high-affinity ligands at the benzodiazepine binding site of the GABA(A) receptor, prompted a study of 3-acyl-1,4-dihydro-4-oxoquinoline (3-acyl-4-quinolones). In general, the affinity of the 3-acyl derivatives was found to be comparable with the 3-carboxylate and the 3-carboxamide derivatives, and certain substituents ( e. g., benzyl) in position 6 were again shown to be important. As it is believed that the benzodiazepine binding site is situated between an alpha-and a gamma-subunit in the GABA(A) receptor, selected compounds were tested on the alpha(1)beta(2)gamma(2s), alpha(2)beta(2)gamma(2s) and alpha(3)beta(2)gamma(2s) GABAA receptor subtypes. The 3-acyl-4-quinolones display various degrees of selectivity for alpha(1)-versus alpha(2)- and alpha(3)- containing receptors, and high-affinity ligands essentially selective for alpha(1) over alpha(3) were developed. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.05.049

文献信息

• Charge-Directed Conjugate Addition Reactions of Salts of Unsaturated β-Keto-Esters
  作者：Manning P. Cooke、John-Yan Jaw

  DOI：10.1080/00397919208019074

  日期：1992.8

  Abstract Strong nucleophiles undergo conjugate addition reactions with enolates of Nazarov-type reagents. Yields are strongly affected by substitution patterns and the metal cation employed.

  摘要 强亲核试剂与 Nazarov 型试剂的烯醇化物发生共轭加成反应。产率受取代模式和所用金属阳离子的强烈影响。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Palani Anandan

  公开号：US20080019978A1

  公开（公告）日：2008-01-24

  The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

  本发明提供了式（I）的化合物及其药学上可接受的盐，溶剂化合物，酯和互变异构体，其中： Q选自以下组： L选自以下组： 本发明还提供了包含一种或多种式（I）化合物的药学组合物以及使用式（I）化合物的方法。
• Nitrogen-containing heterocyclic compounds and methods of use thereof
  申请人：Palani Anandan

  公开号：US20070066630A1

  公开（公告）日：2007-03-22

  The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

  本发明提供了式（I）化合物及其药学上可接受的盐、溶剂化合物、酯和互变异构体，其中：Q选自以下组：L选自以下组：包括一种或多种式（I）化合物的药学组合物，以及使用式（I）化合物的方法。
• ORTHO-CONDENSED 2-PYRIDINONE DERIVATIVES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1885726B1

  公开（公告）日：2016-12-14
• US7723342B2
  申请人：——

  公开号：US7723342B2

  公开（公告）日：2010-05-25